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Background: Positive expiratory pressure (PEP) devices are an important element of the
management of cystic fibrosis, and of other respiratory diseases. Whereas there have been
reports in the literature of contamination of airway clearance devices and their surfaces
by microbial pathogens, there is little evidence available regarding such contamination
and its contribution to respiratory infection.
Aim: To establish whether pathogenic bacteria can contaminate PEP devices in the con-
text of normal cleaning and maintenance practices.
Methods: Patients’ home-use clearance devices were brought to a routine clinic
appointment and collected for microbiology sampling and analysis. The patients were
provided with replacement devices. Nineteen such devices were collected from 17
patients, reflecting use of multiple devices by some patients. Swabs were taken and
cultured from each patient’s used device, the patient’s airway, as well as from new
unopened and unused devices that acted as controls.
Results: Seven of 19 devices (37%) tested positive for presence of pathogenic bacteria.
Device-cleaning methods varied among patients and non-sterilization methods were found
to be ineffective at removing pathogens. Microbial species found on the devices did not
correlate with those identified from airway swabs.
Conclusion: This study demonstrates the presence of pathogens on positive expiratory
pressure devices. The potential for transmission of these pathogens to the patient’s airway
and the risk of infection remains unclear and requires further study.
ª 2021 The Authors. Published by Elsevier Ltd
on behalf of The Healthcare Infection Society. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Medicine, University of
þ353-(0)86-0430739.
Dunne).
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Cystic fibrosis (CF) is a condition that affects the lungs,
pancreas and intestines predominantly [1,2], leading to severe
morbidity and early mortality [3]. It is most prevalent in Europe
and North America, whereas East Asia has the lowest number of
cases per capita [4]. Globally, Ireland has the highest preva-
lence of CF, with 2.98 cases per 10,000 population [4e6]. It has
been predicted that the prevalence of CF in western European
countries, including Ireland, could double by 2025, translating
to a 22% increase in paediatric patients with CF and a 70%
increase in adult patients with CF in Ireland [5].
CF is caused by the absence or malfunction of cystic fibrosis
transmembrane conductance regulator (CTFR) protein,
resulting from a mutation of the CTFR gene [3,7,8]. The CTFR
protein regulates epithelial anion transport and mucociliary
clearance [3,7], both of which are characteristically defective
in CF [7]. The CF airway is, consequentially, a mucus-rich
environment [9], optimal for bacterial colonization and
growth [1,10e13]. Therefore, respiratory infection with
pathogenic bacteria, such as Staphylococcus aureus, Haemo-
philus influenza, Burkholderia cepacia complex, and Pseudo-
monas aeruginosa, occurs frequently in the CF airway
[9,10,12e15], resulting in recurrent chronic infection,
decreased lung function, and accelerated respiratory disease
[9,13,16e18].
The excess mucus present in the CF airway can cause air-
flow restrictions, which can increase the work of breathing,
create ventilationeperfusion mismatch, reduce gaseous
exchange, and result in obstructions. Hence, airway clearance
is an essential therapeutic procedure for patients with CF
[19e21]. For the past 40 years, chest physiotherapy has been
used to a great extent in clearance of obstructions and
reduction in risk of infection or inflammation [20]. Conven-
tional chest physiotherapy techniques include postural drain-
age with percussion and vibration (aided by a physiotherapist
or relative), and forced expirations (huffing and coughing) [21].
However, these traditional methods of chest physiotherapy are
time-consuming, physically demanding, uncomfortable, not
aesthetically appealing, and are reliant on another person, all
which can lead to a lack of adherence to the regimens [19,21].
Technological solutions have been explored to meet these
challenges. Positive expiratory pressure (PEP) (e.g. TheraPEP)
and oscillating positive expiratory pressure (OPEP) (e.g. Aero-
bikA, Flutter) devices (hereafter known collectively as PEP
devices) have now become ubiquitous in the treatment of CF
[22e24]. Such devices reduce mucus viscoelasticity, aid mucus
mobilization, and subsequently promote mucus clearance, by
forcing the airways open for longer during exhalation by
increased resistance (PEP devices) or short pulses of resistance
(oscillating intrapulmonary pressure) (OPEP devices)
[19,23,25e30]. When used correctly, these devices are proven
to be as effective as traditional chest physiotherapy methods
[21,31e33].
Inefficient cleaning and disinfection of PEP devices may
pose a health risk to patients with CF, yet a consensus best
practice standard for these regimens remains to be estab-
lished. Cleaning is defined as the physical removal of foreign
material, such as microbes, dirt and impurities from surfaces
and objects, normally accomplished using water with deter-
gents or enzymatic products, while the purpose of disinfectionis to kill microbes on objects, usually achieved through chem-
ical or thermal means [34]. Despite recommendations from the
US Centers for Disease Control and Prevention (CDC) that PEP
devices undergo ‘high-level disinfection’ [35], there are no
official guidelines for cleaning or disinfecting PEP devices.
Notably, the Cystic Fibrosis Foundation (CFF) has endorsed
guidelines for cleaning and disinfection of aerosol therapeutic
devices (nebulizers) [36,37]. However, manufacturers’ rec-
ommendations for cleaning and disinfecting PEP devices can
differ from those for nebulizers [22,36e38], and can vary
greatly between devices [36]. Specifically, it has been noted
that some PEP device manufacturers recommend to clean their
device with tap water, which contradicts CFF guidelines for
cleaning nebulizers [22,37,38]. Interestingly, cleaning with tap
water has been proposed as a source of Stenotrophomonas
maltophilia detected in a PEP device used by a CF patient [22].
To the best of our knowledge, only one previous published
study has investigated the potential for bacteria to colonize
PEP devices [38]. The authors of that study reported the
presence of bacteria, including Staphylococcus pasteuri,
Staphylococcus warneri, Corynebacterium spp., Pseudomonas
stuzeri, Moraxella spp., and Streptococci spp., in 50% of
devices tested after cleaning. That group did not observe an
association between the bacteria found in the devices and
those detected in the patients’ sputum [38]. Given the high
prevalence of CF in Ireland, and the now expansive range of
pathogens detected in CF patient airways, the association
between these core elements of CF therapy and the potential
for harmful lung infection in this vulnerable population war-
rants further clarification. Accordingly, our study aimed to
investigate the potential for PEP devices to act as reservoirs for
bacteria in the context of normal cleaning, disinfection, and




This single-centre study was performed in an outpatient
department (OPD) at a large regional tertiary hospital in Lim-
erick, Ireland (UHL). Approval for this study was granted by the
UHL Ethics Committee. Participants included a convenience
sample of paediatric patients with CF, who were using a PEP or
OPEP device, attending the OPD for routine clinic or annual
review visits. There were no exclusion criteria for this study.
Study design
Patients were asked to bring their current PEP device to a
scheduled OPD appointment. To ensure that their normal rou-
tine of device maintenance and cleaning was not disrupted,
patients were given no further instructions regarding the study
prior to their OPD appointment. At the start of the clinic
patients were introduced to the study, information was pro-
vided, and informed consent obtained. Information on the
patient’s normal device-cleaning practices was obtained from
the parent or guardian, who was asked to complete a short
survey (Supplementary Appendix) while at the clinic. Infor-
mation on airway infections that occurred prior to and fol-
lowing their OPD appointment was obtained retrospectively. As
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and patient clinical status recorded during the appointment. In
addition, the attending respiratory physiotherapist obtained
cough swabs by asking the patient to cough on a cotton-tipped
swab placed in, but not touching, the posterior pharynx.
With the patient’s consent, their device was taken and a
replacement device provided for future use. To reduce con-
tamination during device handover and sampling, all handling
of the patient’s PEP device by researchers was performed using
sterile gloves. The device mouthpiece was sealed with sterile
latex. Sterile saline solution (0.9% w/v in H2O) was injected
into the device until the device was filled. Following gentle
agitation for 10 s, the seal was removed and the saline solution
decanted into a sterile container. The saline solution was
transferred to the microbiology laboratory immediately on ice
for analysis.
Bacterial identification
The wash saline solution was vortexed for 30 s and 100 mL
(undiluted) was transferred on to tryptic soy agar (TSA) plates
for culture and incubated for 48 h at 30C  2. If colonies were
present after incubation, one subculture was transferred and
inoculated to each of the following media: Columbia blood
agar, MacConkey, and TSA agar. These agar plates are used
regularly to identify bacterial infection in patients with CF
[39].
Further testing of the sample was used to confirm presence
of indicated organisms (Enterobacterales, P. aeruginosa, or
staphylococci) and enterococci. Samples underwent Gram
staining. If bacteria were Gram positive, a catalase test was
performed subsequently. Samples yielding a positive catalase
test underwent Vitek 2 (bioMérieux, Marcy l’Etoile, France)
biochemical testing for organism identification. Samples
yielding negative catalase test were transferred to Slanetz and
Bartley medium, on which a bile aesculin test was used to
identify enterococci species. Gram-negative colonies were
subjected to oxidase testing. Oxidase-positive colonies
underwent Vitek biochemical identification. Oxidase-negative
colonies that were lactose-fermenting were considered to be
Enterobacterales. If the colonies were oxidase negative and a
non-lactose fermenter, a Vitek biochemical identification was
performed. A positive control was provided by culturing
S. aureus NCTC 12981 on TSA agar. A negative control was
established by filtering 100 mL of sterile water through a sterile
funnel and placing the membrane filter on TSA agar.
Slides were prepared for ZiehleNeelson staining (an acid-
fast stain used to detect mycobacteria) [40-42]. In brief, car-
bolfuschin was applied to the wash saline solution on a slide,
followed by heat fixation by passing the slide through a flame.
The stained cell suspension was decolorized by applying acid
alcohol for 20 s. Finally, a counterstain of Methylene Blue was
applied to the slide for 30 s and the slide was rinsed and
allowed to dry.
Unopened device sampling and culture
Unused devices sealed in their original packaging were
swabbed and used as a control. Unopened Aerobika (Trudell
Medical International, London, ON, Canada), TheraPep
(Smiths Medical, Minneapolis, MN, USA), and other devices
were sampled for the presence of bacteria. The devices wereremoved from the packaging within a biosafety cabinet, with-
out handling. All swabs (viscose) were submerged in 2 mL
sterile phosphate-buffered saline (PBS) before use. The outside
of the device and inside of the packaging were swabbed and
the swabs were returned to the PBS. The exterior of the device
was swabbed using sterile PBS, which was collected afterwards
in a sterile dish. The inlet and outlet of the device were sim-
ilarly swabbed and then flushed with sterile PBS, which was
also collected in a sterile dish. The device was then fully dis-
assembled, and the interior of the device swabbed and flushed
with sterile PBS, as per other parts of the device. Note that this
procedure differs from that described earlier for testing of
patients’ devices.
A sample of PBS (100 mL) gathered from the flush of each
area of the device was transferred to agar and spread until dry.
Swabs were vortexed for 5 s. Agar was also inoculated from the
swabs using a simple streak. Additionally, PBS (100 mL) from the
swab was transferred to the agar and, similarly, spread until
dry. All samples were inoculated on to plate count agar (PCA)
and LuriaeBertani (LB) agar, incubated at 35C for 48 h, in
aerobic and anaerobic conditions. Suitable control agar plates
were also included to ensure that media (PCA and LB agar
plates not opened in the biosafety cabinet), the environment
(PCA and LB agar plates opened in the biosafety cabinet), and
PBS (PCA and LB agar plates spread with sterile PBS that was
used to flush the devices) used were sterile.Results
Patient demographics
A total of 17 paediatric patients with CF were recruited, of
whom six (35%) were female. The mean age of patients at the
time of their OPD appointment was 9.8  4.12 years (range:
3.8e17.5). The CF mutation F508del was found to be homo-
zygous in 58% of patients, and heterozygous with a second
disease causing mutation in the remainder.Survey results
Nineteen devices were used by the children, including
Aerobika (n ¼ 14), TheraPep (n ¼ 4), and other (n ¼ 1). Two
patients used two devices concurrently: Aerobika and Thera-
Pep; Aerobika and other devices. The devices were in use for a
median of 6.0  9.00 months (range: 3e48). Fourteen patients
(82%) reported using their device(s) at least once a day
(Table I).
Twelve patients stated that they completed a cleaning
regimen on their PEP device (14 devices), with eight devices
(42%) cleaned after every use. Four devices (21%) were not
cleaned. The remaining devices were cleaned every second
day, weekly, or less frequently than once a month (Table I).
Twelve devices (63%) were cleaned using the manufacturers’
instructions for cleaning. The most common cleaning method
used by the patients was to wash the device with soapy water
and leave the device to air dry (86% devices). This cleaning
regimen lasted an average of 10.8  14.07 min. All but one of
these devices were cleaned as per the manufacturers’
instructions. One patient did not recall the manufacturer’s
cleaning instructions but rather cleaned the device with soapy
water and allowed to air dry (device 8) (Table I). Overall,
Table I
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B. Linnane et al. / Infection Prevention in Practice 3 (2021) 100153 5patients spent a median of 5.0  18.00 min cleaning their
device.
Two patients described using a presumed sterilization
process instead of a regular cleaning regimen. Although both
patients sterilized their devices using boiling water, one
patient sterilized their device after each use (device 14)
whereas the other sterilized their device less frequently than
once a month (device 18) (Table I). Patients attempted to
sterilize their device using a number of techniques: steam
(n¼ 3, 21%), boiling water (n¼ 4, 29%), chemical (e.g. Milton)
(n ¼ 3, 21%) and microwaving (in hot water) (n ¼ 4, 29%). The
time that patients took to sterilize their device ranged from 2
to 120 min (median: 5.0  15.00). Five devices were never
sterilized by the patients or their caregivers. Of these, four
were cleaned regularly (after every use or every second day)
using soapy water. One device was neither cleaned nor
sterilized (device 4) (Table I).
Bacterial species present in patient devices
Bacteria were cultured from all patient devices. On aver-
age, four bacterial species were cultured from PEP devices
(ranging from two to seven species). The majority of cultured
bacteria were identified as normal respiratory tract flora;
however, bacteria with pathogenic potential were cultured
from seven devices (37%). The most common species cultured
from devices were Bacillus spp. (n ¼ 12), Micrococcus spp.
(n ¼ 9), and coagulase-negative staphylococci (n ¼ 8)
(Table II). Furthermore, Stenotrophomonas maltophilia was
cultured from five devices, and Curtobacterium flaccumfa-
ciens, Kocuria rosea, Moroxella spp. (not catarrhalis), Pae-
nibacillus glucanolyticus, Proteus spp. and Pseudomonas
koreensis were also cultured from 2 devices. There was no
statistically significant difference between the mean number
of bacterial species cultured from each device type (Aerobika
4.0 1.33 vs TheraPep 4.0 1.26 vs other 3.0; P¼ 0.867, one-
way analysis of variance).
The length of time patients had owned their device, fre-
quent usage, cleaning frequency, method, and length of time
when cleaning had no discernible effect on whether bacteria
were present in patient devices, the number of bacterial
species in devices, or on the type of bacteria in devices
(normal lung flora or pathogen). Similarly, sterilization fre-
quency and length of time involved in the process had no
effect on the same variables. The relatively low number of
devices made it difficult to draw substantive conclusions from
investigations of cleaning and sterilization methods, and their
effect on bacterial colonization. However, some interesting
observations that require further investigation were recor-
ded. Notably, coagulase-negative staphylococci were not
cultured from a device that was presumed sterilized using a
microwave sterilization technique, contrasting with three of
five devices that were found to be colonized having under-
gone a boiling-water-based sterilization technique.
Microbial assessment of new unused devices
New unused Aerobika (n ¼ 2), TheraPep (n ¼ 2), and other
(n ¼ 1) devices were analysed to determine the presence of
bacteria. Staphylococcus epidermidis was cultured from the
PBS used to flush the inside of an Aerobika device, whereas
Bacillus mojavensis (typically soil-borne) was detected on the
Table II
Bacteria cultured from used devices of patients with cystic fibrosis









No. of devices from which bacteria were cultured 19 (100%) 14 (100%) 4 (100%) 1 (100%)
Bacillus spp. 12 (63%) 10 (71%) 2 (50%) NCc 0.298
Coagulase-negative staphylococci 8 (42%) 6 (43%) 1 (25%) 1 (100%) 0.395
Curtobacterium flaccumfaciens 1 (5%) 1 (7%) NC NC 0.828
Kocuria rosea 1 (5%) 1 (7%) NC NC 0.828
Micrococcus spp. 9 (47%) 2 (14%) 2 (50%) 1 (100%) 0.539
Moroxella spp. (not catarrhalis) 1 (5%) 1 (7%) NC NC 0.828
Paenibacillus glucanolyticus 2 (11%) 2 (7%) NC NC 0.671
Proteus spp. 1 (5%) 1 (14%) NC NC 0.828
Pseudomonas koreensis 1 (5%) NC 1 (25%) NC 0.138
Stenotrophomonas maltophilia 5 (26%) 4 (29%) 1 (25%) NC 0.820
NC, not cultured.
a A device from a wide market selection, excluding Aerobika and TheraPep.
b c2-Test comparing abundance of species cultured from various devices.
B. Linnane et al. / Infection Prevention in Practice 3 (2021) 1001536inside of the packaging from a TheraPep device. There was no
growth on control media (used to check the PCA and LB media,
the environment, and the PBS used).
Airway bacteria and device bacteria compared
Most patients had bacteria isolated from their airway (n ¼
15, 88%) at the time of sample collection at their OPD
appointment. Normal lung flora were cultured from the
majority of patient airways; however, pathogens were detec-
ted in the airways of five patients (29%). These included
S. aureus (n ¼ 3), H. influenza (n ¼ 2), P. aeruginosa (n ¼ 1),
Escherichia coli (n¼ 1), and Aspergillus fumigatus (n¼ 1). Two
patients had more than one pathogen cultured from their air-
ways at the time of their OPD appointment. In each case, three
bacterial species were co-isolated from the airways (S. aureus,
H. influenzae, E. coli and S. aureus, P. aeruginosa,
A. fumigatus). There were no common pathogenic bacteria
found in both the patient airway, prior to and at the time of the
OPD appointment, nor in the devices that they had used.
Discussion
This single-centre small group study aimed to determine
whether PEP devices may pose an airway infection risk for
paediatric patients with CF by acting as pathogen reservoirs.
There are previous reports indicating contamination of home-
use airway devices with pathogenic species [43e45], and it
has been demonstrated that species such as enterococci and
staphylococci can survive for months on plastics [46] such as
those used in the manufacture of PEP devices. Notably, PEP
devices are not distributed typically as sterile devices, but
rather have beenmanufactured in such a way as to eradicate or
reduce their microbial load. However, links between device
contamination and patient infection have not been clearly
established in the literature and remain hypothetical. Pro-
posed mechanisms mediating such infection include the
transfer of environmental bacteria to the devices and sub-
sequently into the patient airway during use, as well as the
transfer of pathogenic species to the device from the patientairway and their reintroduction to the patient airway from the
device, leading to recurrence following treatment (e.g. anti-
microbial therapy for infection) [38]. For example, Greenwood
et al. reported that 12 of their 60-participant cohort involving
patients with CF and chronic P. aeruginosa infection were
found to have pathogenic microbe contamination of nebulizer
devices, while only one patient was found to have a correlating
contamination of both their device and a sputum sample by the
same bacteria species [44]. Similarly, our data did not find
commonality between the bacteria collected from patient
airway swabs and bacteria isolated from the patients’ devices.
The presence of bacteria with pathogenic potential on
seven of 19 devices tested as part of this study is a concerning
finding. The multidrug-resistant, opportunistic bacterium
Stenotrophomonas maltophilia, for example, which was found
on five devices among our patient group, has been associated
with hospital-acquired infections affecting patients with CF,
among others [47]. Indeed, S. maltophilia is increasingly being
isolated from the respiratory tract of patients with CF [48,49].
Interestingly, it was detected in an airway culture from a
patient whose device was positive for S. maltophilia eleven
months previously. Further, it has been determined as asso-
ciated with infection caused by contaminated medical devices,
including indwelling catheters and ventilation tubes [50], and
previous studies have pointed to an association between
reusable airway devices and transmission of S. maltophilia
among CF patients [51]. Although no clear link between
S. maltophilia and disease progression or mortality in CF has
been established, these bacteria have been shown to cause
pulmonary exacerbations, especially where a patient is
immune-compromised or has a poor baseline lung function
[50]. S. maltophilia has also been demonstrated to have a
negative effect on recovery of CF patients following antibiotic
treatment for pseudomonas infection [48].
Differences in PEP device cleaning and disinfection tech-
niques may contribute to device contamination. Whereas a
majority (63%) of patients in our study followed the manu-
facturers’ cleaning instructions, sterilization was not common
and some patients did not clean the device at all despite a
majority of the participants using the device daily. Further, we
B. Linnane et al. / Infection Prevention in Practice 3 (2021) 100153 7noted that cleaning techniques that did not involve steri-
lization did not eradicate pathogenic bacteria effectively and
that the different disinfection methods adopted may have had
varying effects on separate pathogenic species. Given the
prevalence of Bacillus spp. found, it is reasonable to lack
confidence in these cleaning and disinfection practices
affecting spore-formers, although we did not look specifically
for spores. Overall, our findings correlate with data from
another study in which cleaning achieved complete bacterial
eradication in only 50% of devices [38]. It has been discussed
elsewhere that manufacturers’ advice regarding the frequency
and technique required for device cleaning varies between
manufacturers, and that the frequency at which PEP devices
should undergo high-level disinfection is not clear from the CDC
guidelines [38]. Given that context, it seems reasonable to
suggest that healthcare staff may need to place heightened
emphasis on clear cleaning and disinfection guidance at clinical
appointments, providing unambiguous directions on technique
and frequency. We recommend the discussion of this topic by
Manor et al. who emphasize the importance of in-person
demonstration of cleaning techniques [38]. It also appears
prudent that manufacturers’ guidelines ought to be updated,
and subjected to regulation, if a clear link between device
contamination and airway infection is established in future
studies. Such clear and consistent guidance would likely
improve patients’ understanding and compliance.Limitations and recommendations
The limitation of this study is its small sample size, which
limits generalizability to the CF patient population at large. We
did not perform bronchoalveolar lavage, which could have
provided a more accurate reflection of the presence of lower
airway pathogens and which may or may not have determined a
correlation with device microbial load. In addition, we did not
sample devices or airways for viral or fungal pathogens. Fur-
ther, we utilized conventional culture-based microbiology
rather than more sensitive molecular techniques [45,52].
Despite this, we demonstrated presence of potential patho-
gens. A strength of this study is that patients were not informed
that their devices would be assessed for microbial con-
tamination. In a previous study, which attempted to establish
the presence of contamination of PEP devices in a CF setting,
the authors suspected that patients who were aware of their
objective may have altered their cleaning regimen; con-
sequently they observed a lesser microbial load than antici-
pated [38].Conclusions
This study demonstrates that PEP devices may act as res-
ervoirs for potentially harmful microbial species, and that
cleaning and disinfection techniques commonly used by
patients do not ensure eradication of pathogenic bacteria from
devices. Our data did not establish a clear link between bac-
teria found on PEP devices and those found in patients’ air-
ways, albeit that our sampling was limited in not including
bronchoalveolar lavage. Thus, while there are studies showing
transmission of pathogenic respiratory bacteria to both CF and
non-CF patients from medical devices, there is no available
evidence to definitively establish transmission specifically fromPEP devices. More research is now needed, including larger
group studies, to clarify whether PEP devices contribute to
propagating infection in this susceptible patient population,
both at home and during hospitalization, when they are vul-
nerable to nosocomial outbreaks and infection [52]. Further
review of cleaning and disinfection practices and guidelines,
notably those issued by device manufacturers, may be war-
ranted in light of the varied and ineffective practices shown in
this study. The evolving microbiology of CF-related respiratory
infections, the increasing prevalence of CF, and the advantages
of PEP devices over other respiratory therapies for CF make
device-related pathogen transmission an important topic for
future study.
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